AEON Biopharma, Inc. (AEON) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2024. AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA), a botulinum toxin complex. The company operates as a single segment. Following a merger with Priveterra Acquisition Corp. in July 2023, the company is classified as a "Successor" entity for 2024 reporting, while 2023 data is classified as "Predecessor," limiting direct comparability.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | Q2 2023 (3 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income (Loss) | $164.1 million | $46.1 million | $(15.4) million | $(33.0) million |
| Operating Expenses (Cash Basis) | $7.8 million | $18.1 million | $14.0 million | $27.0 million |
| Cash and Equivalents | $3.4 million | $3.4 million | $2.6 million | $2.6 million |
| Convertible Notes (Fair Value) | $13.3 million | $13.3 million | $0 | $0 |
| Accumulated Deficit | $(427.5) million | $(427.5) million | $(507.9) million | $(507.9) million |
Note: Net income for Q2 and YTD 2024 is driven primarily by non-cash gains related to the change in fair value of contingent consideration ($161.2M and $97.5M, respectively) and other derivative liabilities. Operating losses excluding these fair value adjustments were $7.8M for Q2 and $18.1M for YTD 2024.
Material Changes vs. Prior Period
- Strategic Pivot: In May 2024, the company announced the discontinuation of Phase 2 clinical trials for episodic and chronic migraine after failing to meet primary endpoints. In July 2024, management announced a strategic reprioritization to pursue a Section 351(k) biosimilar regulatory pathway for ABP-450, using AbbVie's Botox as the reference product, focusing on a pivotal study for cervical dystonia.
- Expense Reduction: Research and Development (R&D) expenses decreased by 51% in Q2 2024 compared to Q2 2023 ($4.4M vs. $9.0M) due to the wind-down of migraine trials and headcount reductions. Selling, General, and Administrative (SG&A) expenses also decreased by 33% ($3.3M vs. $4.9M) primarily due to reduced legal fees related to the merger.
- Financing Activity: The company issued $15.0 million in senior secured convertible notes to Daewoong Pharmaceutical Co., LTD. in March and April 2024. These notes accrue interest at 15.79% annually.
- Derivative Accounting: Significant non-cash gains were recorded due to the revaluation of contingent consideration liabilities and the termination of Forward Purchase Agreements (FPAs) with ACM and Polar in March 2024.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. As of June 30, 2024, cash balances were $3.4 million. The company expects sufficient cash to fund operations only into the fourth quarter of 2024. Additional financing is required to fund the proposed pivotal cervical dystonia study and ongoing operations.
- Outlook: The company plans to discuss the proposed biosimilar pathway with the FDA in Q3 2024. Success depends on securing additional capital, which may result in significant dilution to existing shareholders.
- Key Risks:
- Capital Shortfall: Inability to raise additional funds could force the company to cease operations or delay development.
- Regulatory Uncertainty: The biosimilar pathway for a neurotoxin is untested; the FDA may not accept the proposed strategy or may require additional data.
- Third-Party Reliance: The company relies exclusively on Daewoong for manufacturing and supply. A termination of the license agreement could halt operations.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting related to complex transactions and valuation of financial instruments.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next financing round given the Q4 2024 liquidity horizon.
- FDA Engagement: Monitor the outcome of the Biosimilar Initial Advisory Meeting scheduled for Q3 2024.
- Convertible Note Terms: Review the conversion triggers and dilution impact of the $15M Daewoong notes (1.3x conversion multiplier).
- Contingent Consideration: Understand that the reported net income is largely non-cash; verify the probability assumptions used to value the $6.9M contingent consideration liability.
- Internal Controls: Assess the remediation plan for the material weaknesses in financial reporting identified in the filing.